Antigen priming of naive CD4 T cells can generate effector CD4 T cells that produce interleukin 4 (T helper [Th]2-1ike) or interferon-y (Thl-like). Using a system in which priming leads to responses dominated by one or the other of these cell types, we show that varying either the antigenic peptide or the major histocompatibility complex class II molecule can determine whether Thl-like or Th2-1ike responses are obtained. Our results show that peptide/major histocompatibility complex class II complexes that interact strongly with the T cell receptor favor generation of Thl-like cells, while those that bind weakly favor priming of Th2-1ike T cells. Thus, signals from the T cell receptor can influence the differentiation of CD4 T cells into specific types of effector cells.
T
he type of effector CD4 T lymphocyte activated during an adaptive immune response determines the efficacy of the response in protective immunity to pathogens. This, in turn, is controlled by selective generation of distinct subsets of effector CD4 T cells (1, 2) known as Thl cells, which can activate macrophages and release, upon activation, the cytokines IFN-'y and lymphotoxin (3) (4) (5) , and Th2 cells, which induce B cells to secrete IgG1 and IgE antibodies and produce the cytokines II,-4 and I1.-5 (2, 6, 7) . While little is known about the mechanisms by which selective differentiation of naive CD4 T cells into Thl or Th2 effector cells is achieved, cytokines produced in the early phases of some infections clearly have an impact on this process (8) (9) (10) (11) (12) (13) (14) (15) (16) . In this report, we show that the selective generation of a CD4 T cell functional class can also be influenced by the nature of the antigen itself. Specifically, we show that subtle modifications in a peptide used for primary immunization in vivo can lead to selective generation of Thl or Th2 cells. Thus, signals delivered via the TCR can influence CD4 T cell differentiation.
In earlier studies, we have shown that mice primed with human collagen IV (huCollV) developed either IL-4-secreting Th2 cells or IFN-'y-secreting Thl cells, depending on their genotype at MHC class II (17, 18) . Strains of mice having the MHC class II molecule I-A b produced serum antibody in response to huCollV, but did not prime T cells which would proliferate in a secondary response. This was in contrast to mice expressing I-A s, whose T cells proliferated upon rechaUenge, but did not induce an antibody response. This difference was due to selective activation of Th2-1ike CD4 T cells in H-2 b mice and Thl-like CD4 T cells in H-2 s mice (18) . Both mouse strains responded to a single 12-amino acid peptide within the huCollV molecule (19) by generating their characteristic set of CD4 T cells (reviewed in Table 1 ). As the functional class of the response was influenced by the genotype of the MHC class II molecule, which presents peptides to CD4 TCR, we proposed that the ability of MHC class II genotype to control CD4 T cell differentiation could be due to differences in the repertoire of T cells responding to the antigen, or to differences in peptide/MHC class II structure and/or abundance (20) . The former seemed unlikely, because it would link MHC allele specificity to function and is now known to be wrong, since mice transgenic for a known TCR can generate responses dominated by either Thl-or Th2-1ike cells that use the transgene-encoded receptor (21, 22) . We have, therefore, focussed upon the latter possibility, both by measuring the strength of binding of the immunodominant peptide of huColIV to purified MHC class IX molecules and by examining the effect of peptide modification on CD4 T cell subset differentiation. Our results show that the nature of the ligand for the TCK can control the differentiation of naive CD4 T ceils into committed effector cells.
Materials and Methods
Animals. A.SW/SnJ and A.BY/SnJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and used at 6-12 wk of age.
Antigens. Synthetic peptides coding for residues 675-686 of the alpha chain of huCollV were prepared by solid phase chemistry on a peptide synthesizer (model 430-A; Applied Biosystems, Inc., Foster City, CA), and were purified by HPLC.
CD4 T Cell Proliferation
Assays. CD4 T cells were isolated and cultured, as previously described (18) , from mice immunized 10 d previously.
Peptide Binding Assays. I-A + and I-A b molecules were purified, as previously described (23, 24) . The relative avidity was measured by competing binding of radiolabeled reference peptide (ROW), to purified I-A' or I-AL Cytokine mRNA Expression. cDNA was amplified with 35 cycles of PCR (94 ~ for 1 min, 60 ~ for 2 min, 72 ~ for 3 min), using Taq polymerase (Promega Corp., Madison, WI). PCK products were run on 2% agarose gel by electrophoresis. Control cDNA was prepared from the activated Thl clone, C19, which secretes IFN-% but not Ib4, upon activation; the activated Th2 clone, D10, which secretes ID4, but not IFN-% upon activation; and CD4 Cytokine Bioassays. For Ib2 measurement, serial dilutions of supematant from cultures described above were added to 10,000 CTL line indicator cells in the presence or absence of anti-IL-2 antibody. Cultures were pulsed after 48 h with 1 #Ci [3H]dTdR and harvested 18-24 h later. Standard plates were set up with several titrations of recombinant routine IL-2, and units were calculated from standard curves with one unit being defined as the amount of Ib2 that gave half-maximal proliferation. For IFN-3, measurement, dilutions of supernatant were incubated with 5,000 WEHI-279 cells in the presence or absence of anti-IFN-'y antibodies. Proliferation was assessed after 48 h, with 1 U of IFN-y defined as the concentration which gave half-maximal inhibition of WEHI-279 proliferation, calculated from the standard curve obtained with mouse IFN-~/standard (Genzyme Corp., Cambridge, MA). In all assays, inhibition of proliferation was blocked by anti-IFN-%
Results

Relative Binding Avidity of huCollV Peptides to MHC Class II. The binding of the immunodominant huColIV peptide
to MHC class II I-A s and I-A b molecules was determined using affinity-purified MHC class II molecules extracted from B lymphoma cells (23, 24) . The same reference peptide (ROW) was used as a labeled probe for binding to both I-A b and I-A', and its ability as a cold peptide inhibitor was used to standardize binding to the two different MHC class II molecules. ROW bound both I-A s and I-A b well ( Fig. 1) with ICs0 in the 20-40 nM range. Other controls in the experiments were the I-As-restricted epitope myelin basic protein 81-100 (25), which bound I-A + as well as the ROW peptide, but bound with far less affinity for I-A b, and the I-A drestricted peptide staphylococcal nuclease 91-100 (26), which bound both I-A b and I-A s with ICs0 in the 0.5-1.0 #M range. Using this assay, it can be seen ( Fig. 1 ) that the immunodominant peptide of huCollV (wild-type) binds to I-A s 2 x 10a-fold more avidly than it binds to I-A b. These data are consistent with the hypothesis that presentation of different densities of huCollV peptide to T cells can lead to selective priming of Thl or Th2, as observed in earlier studies (20). When mice of I-A b genotype were immunized with progressively higher doses of huColIV wild-type peptide, we did indeed observe a shift from Th2 to Thl. Likewise, increasing the dose of peptide injected into I-A s eventually shut down the production of Thl cytokines. However, we did not observe a dose of huColIV peptide at which the H-2 s mice developed CD4 T ceils making Th2 cytokines. Thus, it appears that dose of MHC/peptide by itself cannot control Thl versus Th2 differentiation.
Mutant ColIV Peptides that Elicit IL.4, Rather than IFN-'/, responses from CD4 Cells in 1-,4 s Mice. The problem with
this type of analysis is that I-A b and I-A s molecules differ by many amino acid residues, and the responding T ceils have developed under different intrathymic selective conditions. Thus, it is difficult to make direct comparisons of T cell responses between strains, even if they differ only at the MHC. To circumvent this difficulty, we have prepared mutants of the huColIV immunodominant peptide that differ in their binding to I-A + or I-A b, but nevertheless could activate a panel of T cell hybrids, specific for the wild-type peptide bound to the appropriate MHC class II molecules, as shown in Figs.  2 and 3 . These peptides were then tested for their ability to prime Thl-or Th2-1ike CD4 T cells in a single strain of mouse.
Two mutant peptides, c~2Glu(5) and ot2Ala(ll), which required higher concentrations than the wild-type peptide to activate a panel of I-As-restricted, huCollV-specific T cell hybridomas were identified (Fig. 2 A) . These peptides also bound to I-A ~ somewhat less well than the wild-type peptide. Purified CD4 T cells from mice primed with c~2Glu(5), o~2Ala(ll), or the wild-type peptide were analyzed for their ability to proliferate to the wild-type peptide in vitro, presented by antigen-presenting cells from I-A s mice. As can be seen in Fig. 2 B, CD4 T cells from c~2Ala(11) and a2Glu (5) showed little, if any, proliferative response in comparison to the response of CD4 T cells from H-2 s mice primed with the wild-type peptide. Messenger RNA (mKNA) was also isolated from the CD4 T cells in these secondary cultures, reverse transcribed into cDNA, and assayed by cytokine~specific polymerase chain reaction for cytokine-specific mRNA. As shown in Fig. 2 C, mKNA specific for IFN-% but not IL-4, was produced by CD4 T cells from H-2 ~ mice that were primed with the wild-type peptide, but not from CD4 T cells primed with the mutant peptides, a2Ala(11) and o~2Glu (5), and restimulated with the wild-type peptide. By contrast, IL-4 m R N A appeared only in CD4 T cells from H-2 s mice primed with a2Ala(11) and o~2Glu(5) and restimulated by the wild-type peptide. Thus, a decrease in the ability of the MHC class II/peptide complex to activate a group of huCollVspecific T cell hybridomas led to a change in the differentiation of naive CD4 T cells upon priming, as reflected in a change in cytokines produced from IFN-3, to ILo4. This change correlates much better with the differences in the ability to activate a panel of hybridomas specific for wild-type huCollV than with binding to I-A s.
Mutant huCollV Peptides that Stimulate I-A b-specific Hybrids lO0-fold Better Can Prime Thl-like CD4 T Cells in 1-1-2 b
Mice. To analyze CD4 T cell differentiation in H-2 b mice, one peptide with an Ala substitution at position 10, o~2Ala(10), was identified that had an 80-fold increased ability to activate a panel of H-2b-restricted huCollV-specific T cell hybridomas (Fig. 3 A) . Its ability to bind I-A b was not distinct from that of the wild-type huCollV peptide. When c~2Ala(10) was used to prime H-2 b mice, the CD4 T cells revealed an excellent recall proliferative response to the wildtype peptide presented by H-2 b antigen-presenting cells, whereas priming with the wild-type peptide did not (Fig.  3 B) . Analysis of cytokine mKNA expression of the CD4 T cells restimulated in vitro with wild-type peptide demonstrated that CD4 T cells from mice primed with the wildtype peptide made IL-4, but not IFN-'r, mRNA, as shown previously (Table 1) , but CD4 T cells from mice primed with the mutant peptide ol2Ala (10) no longer expressed IL-4 mKNA, but IFN-'r mKNA (Fig. 3 C) . Thus, in this case (18), from mice immunized 10 d previously with 2 #g. 2 x 10 s CD4 T cells/well were cultured with the wild-type peptide (0.05-50 #g/ml) and 2 x 105 T-depleted splenocytes (mitomycin C-treated) as antigen presenting cells. Cultures were incubated for 72 h, followed by an overnight pulse with 1 #Ci/weU [3H]thymidine. The background cpm without antigen was < 1,500 and has been subtracted from the results. Plotted values represent mean + SD of triplicate cultures. All experiments were repeated at least three times. (C) Cytokine mKNA expression upon priming H-2 s (A.SW) mice with mutant and wild-type peptides. CD4 T cells from mutant and wild-type peptide-primed H-2 S (A.SW) mice (primed with 2 #g peptide/mouse) were isolated from the local lymph nodes and were cultured in 24-well plates at 2 x 106 cells/well in the presence of 10 #g/ml wild-type peptide and 1 • 106 syngeneic T-depleted splenocytes (mitomycin C-treated) from normal, nonimmunized, syngeneic mice. After 48 h, mKNA was made (Micro-Fast Track; Invitrogen, San Diego, CA); cDNA from 2 x 104 cells was prepared and used for each PCR and was equalized using CD3/~ as a control. These sequence data are available from GenBank/EMBL/DDBJ under accession numbers K00083 (IFN-3~), X05064 (IL-4), and X02339 (CD3~). Fig. 2 legend and Materials and Methods. The response of the huCollVspecific, l-Ab-restricted hybridoma was determined as described in the Fig. 2 legend. (B) The proliferative response of CD4 T cells from wild-type and mutant peptide-primed H-2 b (A.BY) mice (see Fig. 2 legend) . (C) Cytokine mRNA expression upon priming of H-2 b (A.BY) mice with mutant and wild-type peptides (see Fig. 2 legend and Materials and Methods).
as well, the ability of an huCollV peptide to interact with M H C and the T C R gives rise to a phenotypically distinct response.
Priming Dose of Peptide Regulates the Type of Effector CD4 T Cells Response in 1-1-2 ~. Given that our initial findings
showed that increasing the priming dose of huCollV wildtype peptide in H-2 s leads to a shift from Th2 to Thl cells (20) , and given that the mutant peptide ot2Ala(ll) could prime Th2 cells in H-2 s mice, we tested whether increasing the priming dose of a2Ala(11) would lead to a shift in priming from Th2 to Thl cells in H-2 ~ mice as well. CD4 T cells from mice primed with either 2/~g or 50/~g of wild-type or mutant peptides were analyzed for I1:4 or IFN-3' production in vitro upon restimulation with the wild-type peptide. As can be seen in Fig. 4 , m R N A specific for IFN-y and IFN-y protein were observed after restimulation when the CD4 T cells were derived from wild-type or ot2Ala(ll) primed mice. No I1:4 was observed from these same primed CD4 T cells. However, when CD4 T cells were derived from mice primed with 2 #g ofpeptide, the CD4 T cells from ot2Ala(ll)-primed mice shifted from IFN-3' to II:4 production, whereas the CD4 T cells from wild-type peptide-primed mice produced IFN-3'. These data, taken together, suggest that the real variable in this system is the interaction of the peptide/ M H C class II complex with the TIER, and that this can be adjusted either through altered binding to MHC, or through altered binding of the complex to a TCR.
Discussion
These studies show that the nature of the complex ligand-comprising peptide bound to an M H C class II mole- Figure 4 . Increasing the priming dose changes the type of effector CD4 T cells generated in H-2' mice. CD4 T cells from H-2 s (A.SW) mice primed with 50 ~g (A) or 2/~g (B) of mutant or wild-type peptide were analyzed for cytokine mRNA expression, as described in Fig. 2 . Supernatants were tested for IFN-y production, as described in Materials and Methods, and yielded the following results: Priming with: 50/~g-wildtype peptide = 27 U/ml; ot2Ala(ll) mutant peptide = 6 U/ml; priming with: 2 #g-wild-type peptide = 18 U/ml; c~2Ala(11) mutant peptide = < limits of detection. The limit of detection in this experiment was 0.5 U/ml rlFN-y. No Ib4 was detected by bioassay, as has been reported previously (18 (21, 22, 27) . The present studies show that similar effects occur with in vivo priming, which may account for the surprising finding that MHC class II genotype can control the functional differentiation of CD4 T cells in response to huCollV. The implication of this finding is twofold. Firstly, it suggests that signals delivered via the TCR can control the differentiation of CD4 T cells into their selective effector cell types. How these signals differ is not known; it may be a quantitative difference in the intensity of signaling, or it may reflect the types of altered signaling that account for differential responses of mature T cells to peptides and their variants (28) (29) (30) (31) . A simple view of the mechanism acounting for the generation of distinct effector functions is that the extent of TCR aggregation leads to different intracellular signals. This might be due to differences in the threshold of signals needed for distinct cytokine gene expression, which may in turn be controlled by TCR occupancy. Alternatively, it might be due to the differential participation of costimulatory molecules. If TCR aggregation is inefficient, there may be a corresponding deficiency in the induction of costimulatory molecules important in the selective generation of Thl or Th2 T cells.
Secondly, these results suggest that high MHC class II/ peptide density on the antigen-presenting cell surface favors Thl-like responses, while low ligand densities favor Th2-1ike responses. If this interpretation is correct, it has important implications for allergy. Allergens are not known to provoke inflammatory reactions that would generate the cytokines necessary to promote Th2-1ike differentiation; however, they are presented to the human immune system at very low dose, leading to IgE synthesis. Moreover, desensitization is generated by injecting successively higher doses of allergen. Likewise, the highest ligand densities are likely to be generated by B cells binding soluble protein antigens and by macrophages infected with intracellular pathogens. Priming in these cases appears to favor generation of Thl-like cells. Thus, the outcome of priming CD4 T cells can be determined, both by the cytokines present in the site of priming and by the antigen itself. Which of these is more important in a given immune response must be determined by direct analysis.
